Clinical trial · Observational
Study to Assess the Feasibility in Bile cfDNA of Resectable Biliary Tract Carcinomas
A Single-Center Exploratory Study to Assess the Feasibility in Bile cfDNA of Resectable Biliary Tract Carcinomas by Using Burning Rock Gene Testing Platform
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study intends to use Onconscreen plus 520 Panel (Burning Rock, China) to conduct NGS testing in matched tissue, blood , and bile samples of patients with Resectable Biliary Tract Carcinomas（BTC）. In order to explore thefeasibility in bile cfDNA of BTC，we will collect relevant clinical information and follow-up treatment information. This study aims to reveal the effectiveness, accuracy, and feasibility in bile, as compared to tissues and blood samples.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| This Study Aims to Reveal the Effectiveness, Accuracy, and Feasibility in Bile | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Next generation sequencing | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- bile group
- description
- bile samples from 20 resectable BTC patients with 520 Panel sequencing (bile10000X)
- interventionNames
- Diagnostic Test: Next generation sequencing
- label
- Tissue group
- description
- tissue samples from 20 resectable BTC patients with 520 Panel sequencing (tissue1000X)
- interventionNames
- Diagnostic Test: Next generation sequencing
- label
- Plasma group
- description
- plasma samples from 20 resectable BTC patients with 520 Panel sequencing (plasma 10000X)
- interventionNames
- Diagnostic Test: Next generation sequencing
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients who are diagnosed with diagnosed with BTC (including IHCC、EHCC、GBC)by histology or cytology 2. Patients who signed informed consent form; 3. Patients who agree and have the ability to follow the planned research visits, provide surgical tissue, blood, and bile samples, provide clinical information, and cooperate with other research steps. Exclusion Criteria: a.Patients who be deemed unsuitable for enrollment by the researchers.
References
Publications (0)
Data not yet available